Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

John Huber

Nurse Practitioner, Family Morgantown, WV Nurse Practitioner

NPI 1649521758 CMS profile 10697052

6000 Memorial Church Dr, Morgantown, WV 26501

Open in the dashboard

General payments

$11,549

687 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Huber of Morgantown, WV is reported in the CMS Open Payments database as having received $11,549 across 687 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,133 112
2024 General $2,776 163
2023 General $2,514 166
2022 General $1,941 137
2021 General $2,185 109

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Huber
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to John Huber were reported at $2,133. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year John Huber Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,185 $124 $35–$379 $132
2022 $1,941 $141 $44–$430 $149
2023 $2,514 $154 $49–$476 $160
2024 $2,776 $165 $51–$504 $164
2025 $2,133 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,608 201 payments
  2. AstraZeneca Pharmaceuticals LP $1,823 57 payments
  3. Novo Nordisk Inc $972 49 payments
  4. Lilly USA, LLC $935 62 payments
  5. Pfizer Inc. $662 41 payments
  6. Novartis Pharmaceuticals Corporation $400 34 payments
  7. Exact Sciences Corporation $382 20 payments
  8. Astellas Pharma US Inc $375 21 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $313 19 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $300 18 payments
  11. Other $2,780 165 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,142 685 payments
  2. Consulting Fee $400 1 payment
  3. Education $7 1 payment
Products named General payments · program years 2021–2025
  1. UBRELVY $1,188 68 payments
  2. FARXIGA $806 22 payments
  3. Ozempic $751 36 payments
  4. RYBELSUS $751 36 payments
  5. QULIPTA $688 29 payments
  6. BREZTRI $669 14 payments
  7. LINZESS $544 53 payments
  8. MOUNJARO $515 33 payments
  9. AIRSUPRA $514 17 payments
  10. FASENRA $502 2 payments
  11. Other $9,170 599 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 149 drugs

Part D claims

7,889

Median for Nurse Practitioner: 389

Drug cost

$1,184,182

Median for Nurse Practitioner: $21,885

Branded share of claims

24%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 84 $119,380
Eliquis Apixaban Brand 100 $110,708
Jardiance Empagliflozin Brand 90 $110,637
Ozempic Semaglutide Brand 81 $104,402
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 79 $104,105
Trulicity Dulaglutide Brand 47 $85,815
Farxiga Dapagliflozin Propanediol Brand 62 $75,187
Tresiba Flextouch U-200 Insulin Degludec Brand 25 $51,243
Januvia Sitagliptin Phosphate Brand 29 $39,828
Linzess Linaclotide Brand 36 $36,490

The 10 drugs with the highest cost, of 149 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$55,752

Of which drugs: $11,410

Medicare patients

247

Average age 73

Services billed

974

141 women, 106 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Diabetes 28%
Ischemic heart disease 23%
Depression 19%
Chronic kidney disease 15%
Heart failure 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 30 30 $8,470
Vaccine for influenza for injection into muscle 90662 Office 25 25 $2,016

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 41 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $207
$207 — —
UBRELVY
  • AbbVie, Inc. $151
$151 — —
VRAYLAR
  • AbbVie, Inc. $130
$130 — —
LINZESS
  • AbbVie, Inc. $126
$126 36 —
Veozah
  • Astellas Pharma US Inc $115
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 41 with Patron

Records

687 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record